ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC)

Virchows Archiv

Volumn 469, Issue 5, 2016, Pages 547-552

  Breyer, Johannes ^a   Wirtz, Ralph M ^b,c   Laible, Mark ^d   Schlombs, Kornelia ^d   Erben, Philipp ^e   Kriegmair, Maximilian Christian ^e   Stoehr, Robert ^f   Eidt, Sebastian ^c   Denzinger, Stefan ^a   Burger, Maximilian ^a   Hartmann, Arndt ^f   Otto, Wolfgang ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b STRATIFYER Molecular Pathology GmbH   (Germany)

^c St Elisabeth Hospital   (Germany)

^d BIONTECH AG   (Germany)

^e UNIVERSITY OF MANNHEIM   (Germany)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

ERBB2; ESR1; Grade; MKI67; NMIBC; Stage

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; KI 67 ANTIGEN; MESSENGER RNA; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA, HUMAN; TUMOR MARKER;

AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADULT; CARCINOMA IN SITU; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; URINARY BLADDER NEOPLASMS;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA IN SITU; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; URINARY BLADDER NEOPLASMS;

EID: 84981555037     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-016-2002-1     Document Type: Article

References (26)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:359–386
2. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Roupret M (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64:639–653
3. Prout GR Jr, Barton BA, Griffin PP, Friedell GH (1992) Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group. J Urol 148:1413–1419
4. Otto W, Denzinger S, Fritsche HM, Burger M, Rößler W, Bertz S, May M, Hartmann A, Hofstädter F, Wieland WF, Eder F (2013) Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients. Clin Genitourin Cancer 11:537–544
5. Sylvester RJ, van der Meijden A, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta, T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–465
6. Limas C, Bigler A, Bair R, Bernhart P, Reddy P (1993) Proliferative activity of urothelial neoplasms: comparison of BrdU incorporation, Ki67 expression, and nucleolar organiser regions. J Clin Pathol 46:159–165
7. Wang L, Feng C, Ding G, Ding Q, Zhou Z, Jiang H, Wu Z (2014) Ki67 and TP53 expressions predict recurrence of non-muscle-invasive bladder cancer. Tumour Biol 35:2989–2995
8. Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315–222
9. Choi W, Porter S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152–165
10. Sjödahl G, Lauss M, Lövgren K, Chebil G, Gudjonsson S, Veerla S, Patschan O, Aine M, Fernö M, Ringnér M, Månsson W, Liedberg F, Lindgren D, Höglund M (2012) A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 18:3377–3386
11. Otto W, Denzinger S, Fritsche HM, Burger M, Wieland WF, Hofstädter F, Hartmann A, Bertz S (2011) The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int 107:404–408
12. Rodríguez-Alonso A, Pita-Fernández S, González-Carreró J, Nogueira-March JL (2002) p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma. Eur Urol 41:182–188
13. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, Carrasco JC, Requena MJ, Montironi R (2004) Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur Urol 45:606–612
14. Gontero P, Gillo A, Fiorito C, Oderda M, Pacchioni D, Casetta G, Peraldo F, Zitella A, Tizzani A, Ricceri F (2014) Prognostic factors of ‘high-grade’ Ta bladder cancers according to the WHO 2004 classification: are these equivalent to ‘high-risk’ non-muscle-invasive bladder cancer? Urol Int 92:136–142
15. Kumar S, Prajapati O, Vaiphei K, Parmar KM, Sriharsha AS, Singh SK (2015) Human epidermal growth factor receptor 2/neu overexpression in urothelial carcinoma of the bladder and its prognostic significance: is it worth hype? South Asian J Cancer 4:115–117
16. Jalali Nadoushan MR, Taheri T, Jouian N, Zaeri F (2007) Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder. Urol J 4:151–154
17. Zhao J, Xu W, Zhang Z, Song R, Zeng S, Sun Y, Xu C (2015) Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. Int Urol Nephrol 47:87–94
18. Amsellem-Ouazana D, Bièche I, Molinié V, Elie C, Vieillefond A, Tozlu S, Botto H, Debré B, Lidereau R (2006) Is quantitative real-time RT-PCR an adjunct to immunohistochemistry for the evaluation of ErbB2 status in transitional carcinoma of the bladder? Eur Urol 49:1035–1042
19. Chen PC, Yu HJ, Chang YH, Pan CC (2013) Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. J Clin Pathol 66:113–119
20. Iyer G, Al-Ahmadie H, Schultz N, Hanrahan AJ, Ostrovnaya I, Balar AV, Kim PH, Lin O, Weinhold N, Sander C, Zabor EC, Janakiraman M, Garcia-Grossman IR, Heguy A, Viale A, Bochner BH, Reuter VE, Bajorin DF, Milowsky MI, Taylor BS, Solit DB (2013) Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 31:3133–3140
21. Rajjayabun PH, Keegan PE, Lunec J, Mellon JK (2005) erbB receptor expression patterns in human bladder cancer. Urology 66:196–200
22. Tan W, Boorjian S, Advani P, Farmer S, Lohse C, Cheville J, Kwon E, Leibovich B (2015) The estrogen pathway: estrogen receptor-α, progesterone receptor, and estrogen receptor-β expression in radical cystectomy urothelial cell carcinoma specimens. Clin Genitourin Cancer 13:476–484
23. Shen SS, Smith CL, Hsieh JT, Yu J, Kim IY, Jian W, Sonpavde G, Ayala GE, Younes M, Lerner SP (2006) Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer 106:2610–2616
24. Hsu I, Vitkus S, Da J, Yeh S (2013) Role of oestrogen receptors in bladder cancer development. Nat Rev Urol 10:317–326
25. Teng J, Wang ZY, Jarrard DF, Bjorling DE (2008) Roles of estrogen receptor alpha and beta in modulating urothelial cell proliferation. Endocr Relat Cancer 15:351–364
26. Hoffman KL, Lerner SP, Smith CL (2013) Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation. Horm Cancer 4:24–35